India’s pharma exports surged 6.8% in Q1 FY27, led by vaccines and bulk drugs, with future growth hinging on market diversification and regulatory reforms, especially in the UK and US.
India’s pharmaceutical exports rose 6.8% year on year to $8.10 billion in the first quarter of FY27, according to data from the Pharmaceuticals Export Promotion Council of India, underscoring the sector’s continued resilience even as it faces pressure to widen its product mix and deepen its presence in newer markets.
The strongest gains came from higher shipments of vaccines, bulk drugs and intermediates. Drug formulations and biologicals remained the largest segment, bringing in $5.98 billion and accounting for 73.85% of total exports, while bulk drugs and drug intermediates climbed 13.84% to $1.36 billion. Vaccine exports rose sharply by 35.68% to $390 million and surgical products increased 11.95% to $210 million.
June also finished on a firmer note, with exports up 7.13% from a year earlier to $2.81 billion. Pharmexcil has said the industry must keep pushing product diversification, regulatory compliance and entry into new markets if it is to sustain the current pace. Chairman Namit Joshi said, as quoted by ANI, that India should strengthen its position in generics while building a larger role in complex generics, biosimilars, peptides and other innovation-led categories.
The export mix remains heavily dependent on a few key regions. North America, Europe, Africa and Latin America and the Caribbean together accounted for nearly three-quarters of shipments in the quarter, with North America alone making up 34.28%. The US was the largest single market at $2.50 billion, or 30.89% of total exports, followed by Brazil, the UK, the Netherlands and France. The top 25 destinations accounted for nearly 70% of overseas sales, worth $5.65 billion.
Looking ahead, the UK may become a more important market after the India-UK Comprehensive Economic and Trade Agreement. Pharmexcil has projected that Indian pharmaceutical exports to Britain could rise 8.66% to $981.16 million in FY2026-27 as tariffs are removed on almost all products, improving the competitiveness of Indian generic medicines and supporting tighter supply-chain links, investment and joint work in manufacturing, research and innovation. Separate sector reports have also pointed to stronger US demand and African growth as important drivers, with one industry summary citing 47 final ANDA approvals from the US FDA in April and May and a 24% rise in exports to Africa in the quarter.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
